Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.

Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.

Purpose<br/> Our aim was to determine the role of end-of-induction (EOI) minimal residual disease (MRD) assessment in the identification and stratification of induction failure in patients with pediatric acute lymphoblastic leukemia (ALL) and to identify genetic abnormalities that drive...

ver descrição completa

Detalhes bibliográficos
Principais autores:	O'Connor, D, Moorman, A, Wade, R, Hancock, J, Tan, R, Bartram, J, Moppett, J, Schwab, C, Patrick, K, Harrison, C, Hough, R, Goulden, N, Vora, A, Samarasinghe, S
Formato:	Journal article
Idioma:	English
Publicado em:	American Society of Clinical Oncology 2017

Registros relacionados

Genotype-specific MRD interpretation improves stratification in paediatric acute lymphoblastic leukaemia
por: O'Connor, D, et al.
Publicado em: (2017)

Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003.
por: O'Connor, D, et al.
Publicado em: (2014)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
por: Vora, A, et al.
Publicado em: (2014)

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial
por: Vora, A, et al.
Publicado em: (2014)

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MIRD) clearance in childhood lymphoblastic leukaemia (ALL)
por: Moorman, A, et al.
Publicado em: (2008)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
por: Vora, A, et al.
Publicado em: (2013)

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial
por: Vora, A, et al.
Publicado em: (2013)

Down Syndrome is a significant risk factor for infectious deaths in childhood acute lymphoblastic leukaemia: a retrospective analysis of the infectious deaths on UKALL 2003
por: O'Connor, D, et al.
Publicado em: (2014)

A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.
por: Moorman, A, et al.
Publicado em: (2014)

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MRD) clearance in childhood acute lymphoblastic leukaemia (ALL)
por: Moorman, A, et al.
Publicado em: (2007)

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol.
por: Patrick, K, et al.
Publicado em: (2014)

Outcome of Down syndrome associated acute lymphoblastic leukaemia treated on a contemporary protocol
por: Patrick, K, et al.
Publicado em: (2014)

Risk-directed treatment intensification significantly reduces the risk of relapse among children and adolescents with acute lymphoblastic leukemia and intrachromosomal amplification of chromosome 21: a comparison of the MRC ALL97/99 and UKALL2003 trials.
por: Moorman, A, et al.
Publicado em: (2013)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
por: Patrick, K, et al.
Publicado em: (2014)

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
por: Patrick, K, et al.
Publicado em: (2014)

UKALL 2003, A Randomised Trial Investigating Treatment Intensification for Children and Young Adults with Minimal Residual Disease Defined High Risk Acute Lymphoblastic Leukaema
por: Vora, A, et al.
Publicado em: (2012)

Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.
por: Jenkinson, S, et al.
Publicado em: (2013)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003
por: Samarasinghe, S, et al.
Publicado em: (2013)

Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003.
por: Samarasinghe, S, et al.
Publicado em: (2013)

Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial
por: Nadine Farah, et al.
Publicado em: (2018-07-01)

Post-Remission MRD Kinetics in Children with Acute Lymphoblastic Leukaemia Receiving Augmented BFM Consolidation Compared with Other Regimens Results of the Medical Research Council Trial UKALL2003.
por: Cutting, R, et al.
Publicado em: (2008)

IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome.
por: Russell, L, et al.
Publicado em: (2014)

Post-remission MRD kinetics in children with acute lymphoblastic leukaemia receiving augmented BFM consolidation compared with other regimens: update of results of the Medical Research Council Trial UKALL2003
por: Cutting, R, et al.
Publicado em: (2009)

Improved Outcome for Children and Young Adults with T-Cell Acute Lymphoblastic Leukaemia (ALL): Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
por: Vora, A, et al.
Publicado em: (2008)

Efficacy and Toxicity of Pegylated Asparaginase in the Treatment of Children and Young Adults with Acute Lymphoblastic Leukaemia: Results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003
por: Vora, A, et al.
Publicado em: (2008)

Incidence and Outcome of Osteonecrosis in Children and Young Adults with Acute Lymphoblastic Leukaemia Treated on a Dexamethasone Containing Protocol: Results of the Medical Research Council UK Trial ALL 2003
por: Vora, A, et al.
Publicado em: (2008)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
por: Vora, A, et al.
Publicado em: (2010)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
por: Vora, A, et al.
Publicado em: (2010)

UKALL 2003, A Randomised Trial Investigating Treatment Reduction for Children and Young Adults with Minimal Residual Disease Defined Low Risk Acute Lymphoblastic Leukaemia
por: Vora, A, et al.
Publicado em: (2010)

Profile of Steroid Toxicity During Maintenance Treatment in Teenage and Young Adult (TYA) Patients with Acute Lymphoblastic Leukaemia (ALL)
por: Tomlins, J, et al.
Publicado em: (2012)

Variables affecting kinetics of minimal residual disease clearance in children with lymphoblastic leukaemia; Results of the United Kingdom Medical Research Council (UK MRC) protocols ALL97, ALL97/99 and ALL2003.
por: Vora, A, et al.
Publicado em: (2005)

Polymorphism in the PAI-1 (SERPINE1) gene and the risk of osteonecrosis in children with acute lymphoblastic leukemia
por: Bond, J, et al.
Publicado em: (2011)

Polymorphism in the PAI-1 (SERPINE1) gene and the risk of osteonecrosis in children with acute lymphoblastic leukemia.
por: Bond, J, et al.
Publicado em: (2011)

Delineation of Risk Factors in Paediatric Acute Lymphoblastic Leukaemia with Favourable Cytogenetics
por: Moorman, A, et al.
Publicado em: (2012)

BTG1 deletions do not predict outcome in Down syndrome acute lymphoblastic leukemia.
por: Buitenkamp, T, et al.
Publicado em: (2013)

BTG1 deletions do not predict outcome in Down syndrome acute lymphoblastic leukemia
por: Buitenkamp, T, et al.
Publicado em: (2013)

Advances in acute lymphoblastic leukemia genomics
por: Christine J. Harrison, et al.
Publicado em: (2018-06-01)

Presence of mutations in the NOTCH1 signalling pathway has a beneficial impact on outcome in paediatric T-ALL patients treated on the MRC UKALL2003 trial
por: Jenkinson, S, et al.
Publicado em: (2012)

Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21).
por: Moorman, A, et al.
Publicado em: (2007)

Advances in B-cell Precursor Acute Lymphoblastic Leukemia Genomics
por: Claire Schwab, et al.
Publicado em: (2018-08-01)